Novartis Catches Flu Fever: Second Bid Nets Chiron
Executive Summary
Novartis' first priority upon the completion of its acquisition of Chiron will be to resolve the flu vaccine maker's outstanding manufacturing issues, Novartis Head of Pharma Development Jörg Reinhardt said during an analyst call announcing the deal Oct. 31
You may also be interested in...
Novartis Vaccines Unit Looks To Make Its Presence With New Technologies
With a variety of new vaccines technology in play - such as cell-culture production, novel adjuvants and reverse vaccinology - Novartis' fledgling vaccines unit is at the cutting edge of vaccine development and could become a major player in the revitalized vaccine field
Novartis Vaccines Unit Looks To Make Its Presence With New Technologies
With a variety of new vaccines technology in play - such as cell-culture production, novel adjuvants and reverse vaccinology - Novartis' fledgling vaccines unit is at the cutting edge of vaccine development and could become a major player in the revitalized vaccine field
Novartis’ New Vaccine Division Takes On Evolving Market
Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said